View Older Stories View More Recent Stories

Aug 31, 2020 08:00AM Paul Clark Joins Agenus Board of Directors
Aug 26, 2020 02:48PM Agenus (AGEN) Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer
Aug 26, 2020 02:46PM Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer
Aug 6, 2020 07:30AM Agenus Provides R&D Update & Second Quarter Financial Report
Aug 4, 2020 08:30AM Agenus to Present on Targeting Myeloid Cells in Tumor Microenvironment at the William Blair Biotech Focus 2020 Conference
Jul 29, 2020 02:00PM Agenus R&D update & Second Quarter Earnings Report
Jul 28, 2020 11:24AM Agenus (AGEN) Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals
Jul 28, 2020 11:23AM Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals
Jul 21, 2020 01:31PM Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit
Jun 22, 2020 09:43AM Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Jun 22, 2020 07:04AM Agenus (AGEN), Betta Pharma Announces License Agreement for Balstilimab and Zalifrelimab in Greater China
Jun 22, 2020 07:00AM Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China
Jun 17, 2020 11:06AM Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
Jun 17, 2020 10:53AM Agenus to Present at the Raymond James Virtual Human Health Innovation Conference
Jun 16, 2020 08:12AM Agenus Announces Virtual Annual Shareholders Meeting
Jun 2, 2020 08:31AM Agenus (AGEN) Reports FDA Clearance IND for iNKT Cells to Treat COVID-19 Patients
Jun 2, 2020 08:30AM FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
May 29, 2020 08:00AM ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day
May 14, 2020 08:05AM Agenus (AGEN) NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO
May 14, 2020 08:00AM Agenus NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO
May 13, 2020 09:55AM Agenus (AGEN) Announces FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
May 13, 2020 09:54AM FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
May 7, 2020 08:00AM Agenus First Quarter Results and Update
Apr 28, 2020 11:50AM Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast
Apr 7, 2020 01:05PM Agenus (AGEN) Granted FDA Fast Track Designation for Balstilimab in Advanced Cervical Cancer
Apr 7, 2020 01:04PM Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer
Mar 12, 2020 07:47AM Agenus (AGEN) Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Mar 12, 2020 07:45AM Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Mar 12, 2020 07:30AM Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Mar 10, 2020 09:14AM First QS-21 Royalty Payment Due to Agenus is Triggered
Mar 3, 2020 08:00AM Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast
Feb 20, 2020 09:56AM Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer
Feb 6, 2020 03:12PM Agenus Announces Investor Day on February 20, 2020
Jan 9, 2020 11:01AM Agenus (AGEN) Announces Dr. Jennifer Buell as President & COO
Jan 9, 2020 10:59AM Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO
Jan 8, 2020 08:30AM Agenus Commences Phase 1 trial with AGEN1223
Dec 19, 2019 07:30AM Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
Nov 12, 2019 12:48PM Agenus to Host R&D Day November 15, 2019
Nov 11, 2019 08:00AM Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
Nov 4, 2019 07:00AM Agenus Provides Corporate Update with Third Quarter 2019 Financial Results
Sep 30, 2019 04:34PM Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
Aug 8, 2019 07:42AM Agenus (AGEN) Reports FDA Acceptance of IND Filing for AGEN2373 Triggers $7.5M Milestone Payment from Gilead Sciences Inc. (GILD)
Aug 8, 2019 07:30AM Agenus Milestone Triggers $7.5M Payment
Aug 8, 2019 07:30AM Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jun 13, 2019 03:48PM Agenus to Host Annual Meeting of Stockholders
May 9, 2019 07:30AM Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 3, 2019 01:38PM Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast
Apr 2, 2019 08:34AM Agenus (AGEN) Commences Dosing with Next-Gen Anti-CTLA-4 Antibody
Apr 2, 2019 08:30AM Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
Mar 14, 2019 08:00AM Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
View More Recent Stories View Older Stories